Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
MENLO PARK, Calif., May 09, 2017 -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report preliminary results of the Corplex Donepezil pilot bioequivalence study as well as financial results for the second quarter ended March 31, 2017 on Thursday, May 11, 2017 before the open of the U.S. financial markets. Corium will host a conference call and live audio webcast at 8:30 a.m. Eastern time, 5:30 a.m. Pacific time to discuss its financial results and report on recent progress.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 20268962. The conference call will also be available via a live audio webcast which may be accessed here, or by visiting the Investors section of Corium's website at http://ir.coriumgroup.com/events.cfm. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumgroup.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact: SMP Communications Susan Pietropaolo [email protected] (201) 923-2049
